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Platinum drugs endowed with a novel chemical structure could offer an alternative therapeutic strategy,
allowing to enlarge the spectrum of activity and to overcome the many drawbacks of the well-known
cisplatin (CisPt) and its derivatives [1]. Our group synthetised a new caPt(II)-complex that showed a very
effective cytotoxic effect on triple-negative breast cancer cells and on cell lines partially resistant to cisplatin
[2]. As previously reported Mesenchymal Stromal Cells (MSCs) from different tissues are able to uptake and
then release drugs as free molecules and exosome associated drugs [3,4] suggesting new strategies to be
apply in advanced cell therapy for treating cancer. The application of this strategy is in part depending on the
solubility of the drug in medium and their stability during the drug loading procedure and may be that some
anticancer molecules do not have these features. The same platinum-based drugs have very limited solubility
in culture medium and also can suffer degradation process by pH modification and temperature. In this study,
we compared the in vitro stability of CisPt and caPt(II)-complex and their in vitro activity against human
tumour cell lines. The drug sensitivity of Mesenchymal Stromal Cells (MSCs) and their ability to uptake and
release the drugs was also investigated.
AT-MSCs were isolated by enzymatic digestion with collagenase type I and expanded in StemMACS medium
(Miltenyi Biotec, Germany) until passage 3. Primary cultures were analysed for their proliferation rate (Population
doubling time), clonogenicity (CFU-F assay) and expression of the typical mesenchymal stem cell markers and
multi differentiative ability towards mesodermal lineages. Drug stability was studied following incubation of CisPt
and caPt(II)-complex at 37°C in complete cell culture medium both in the absence and in the presence of a
monolayer of MSCs.
The activity of CisPt and caPt(II)-complex was tested on AT-MSCs and against malignant pleural mesothelioma cell
line NCI-H28 [5], glioblastoma cell line U87 MG [6] and pancreatic adenocarcinoma cell line CFPAC-1 [7] (used
as laboratory standard cancer cell line), by using a MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium)
anti-proliferative assay in 96 multiwell plates [8,9]. AT-MSCs were exposed to Cis-Pt (166.5 µM) or caPt (II)-
complex (85 µM) for 24 hours and the amount of drugs incorporated and released by the cells was evaluated by
the inductively coupled plasma mass spectrometry (ICP-MS). Data were expressed as average ± standard deviation
(SD) and the differences evaluated according to Student’s t-test performed. p values ≤ 0.05 were considered
statistically significant. The linearity of response and the correlation were studied using regression analysis, by Excel
2013 software (Microsoft, Inc.)
The activity of CisPt and
caPt(II)-complex was
evaluated in vitro against
three human cancer cell
lines, (pancreatic
carcinoma CFPAC-1,
glioblastoma U87 and
mesothelioma NCI-H28 )
showed a dose-response
kinetics of inhibition with
a significant coefficient of
correlation (R2).
(A). Against CFPAC-1
proliferation, CisPt was
significantly (p<0.01)
more active (IC50 = 9.64
± 5.10 µM) than caPt(II)-
complex (IC50= 21.25 ±
6.68 µM).
(B,C). A significant higher activity (p<0.05) of caPt(II)-complex was seen both against NCI-H28
mesothelioma cells (IC50 = 19.37 ± 9.57 µM versus 34.66 ± 7.65 µM for cisPt) and against U87 MG
(19.85 ± 0.97 µM versus 54.14 ± 3.19 µM for cisPt). (D). IC50 values (µM) expressed as histogram.
The two drugs were tested both for their cytotoxic (A) and antiproliferative activity (B) on AT-MSCs. As 
evidenced by the linear regression analysis, in the 24 hours cytotoxicity assay the  MSCs showed to have a 
similar sensitivity both to caPt(II)-complex and to CisPt (C). On the contrary, in the antiproliferation test the 
IC50 for the two drugs were significantly (p< 0.05) different (D).
Both CisPt and caPt(II)-complex were studied for their stability following the incubation at 37°C in the complete cell culture
medium both in the absence and in the presence of a monolayer of AT-MSCs. The stability has been evaluated by determining
the dose response inhibiting kinetics against CFPAC-1 proliferation.
(A,C): caPt(II)-complex maintained its ability to inhibit cancer cell proliferation after 24 hours and 9 days of incubation, with
a dose response kinetics similar to that of the fresh drug both if incubated in the absence and presence of MSCs monolayer.
(B,D): CisPt completely lost its anticancer activity after 24 hours (and obviously, after 9 days) in the both two incubation
conditions.
(E,F): By comparing the IC50 values of caPt(II)-complex no significant differences (p<0.05) were observed between the
fresh and the 9 days incubated drug.
To evaluate the amount of the two drugs both in conditioned media (CM) and cell lysates, a IC-MS
analysis was performed, that demonstrated that MSCs were able to incorporate both the drugs. As
reported in figure (A,B) the CisPt found in the lysate was in amount of 2.48 ± 0.16 pM/cell and that
of caPt (II)-complex of 2.49 ± 0.2 pM/cell. To verify their release from the MSCs, the presence of the
two drugs were also determined in the CM. The amount resulted of 1.17 ± 0.07 pM/cell for caPt(II)-
complex and of 2.23 ± 0.06 pM/cell for CisPt respectively. This indicated that at 24 hs of subculture
the drug loaded MSCs released about 47% of the caPt(II)- complex and 88 % of the CisPt.
Our results evidenced that caPt (II)-complex exerts a remarkable anticancer activity in vitro
against the three cancer cells lines studied. While the activity against pancreatic carcinoma cells
exerted by caPt(II)-complex is lower than that exerted by cisPt (21.25 ± 6.68 vs 9.64 ± 5.10 µM)
a significant (p<0.05) higher activity of this new molecule was evidenced both against human
mesothelioma NCIH28 (19.37 ± 9.57 vs 34.66 ± 7.65 µM) and a human glioblastoma cell line U87
MG (19.85 ± 0.97 vs 54.14 ± 3.19 µM).
Concerning the stability, our findings evidenced that caPt(II)-complex is a very stable compound if
compared to CisPt. The treatment of the two drugs at 37°C demonstrated that whereas CisPt
lost all its anticancer activity after only 24 hours of treatment, caPt(II)-complex maintain 100 % of
its activity after a long time of incubation (figure 3). The cancer activity is maintained also if
caPt(II)-complex is incubated in the presence of a monolayer of MSCs confirming that the
molecule did not suffer modification due to cell metabolism and significant variation of pH of
the culture medium produced by the cell growth (figure 3 A,C).
The analytical data on lysates confirmed a significant incorporation of both the molecule that
was very similar (caPt(II)-complex 2.49 ± 0.2 pM/cell and CisPt 2.48 ± 0.16 pM/cell) while the
amount of drug released in the conditioned medium was of 47 % for caPt(II)-complex and
near to 90 % for CisPt. (see figure 4A).
In conclusion, the high stability of caPt(II)-complex together with its significant anticancer activity
against mesothelioma and glioblastoma makes this new platinum derivative a very interesting
molecule able to improve cancer chemotherapy. Furthermore, the low sensitivity of AT-MSCs to
the antiproliferative action exerted by caPt(II)-complex together with their ability to uptake and
release the drug suggest further investigation in order to optimize the drug loading procedure
and verify the possibility to set up a system based on cell mediated delivery of caPt(II)-complex.
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